Involvement of c-Met/Hepatocyte Growth Factor Pathway in Cholangiocarcinoma Cell Invasion and Its Therapeutic Inhibition With Small Interfering RNA Specific for c-Met

• Main Authors: Kawin Leelawat, Surang Leelawat, Panada Tepaksorn, Panthip Rattanasinganchan, Anicha Leungchaweng, Rutaiwan Tohtong, Prasert Sobhon
• Other Authors: Rajavithi Hospital
• Format: Article
• Published: 2018
• Subjects: Medicine
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/23510
• Institution: Mahidol University

Background: Hepatocyte growth factor receptor (c-Met) plays an important role in many functions of cancer cells. We examined the roles of c-Met and its downstream signaling molecules in cholangiocarcinoma cell lines RMCCA1 and HuCCA1. Materials and methods: The expression of c-Met and their signaling cascades were determined in RMCCA1 and HuCCA1 cholangiocarcinoma cell lines by Western blotting. Small interfering RNA (siRNA) specific for c-Met was used to suppress the expression of c-Met. The proliferation, migration and invasion assay were tested in these cholangiocarcinoma cells treated with hepatocyte growth factor (HGF). Results: Activation of c-Met with HGF triggered the signaling via the ERK cascade mediated by sequential phosphorylation of MEK1/2 and MAPK and induction of cholangiocarcinoma cell invasion. The expression of c-Met in cholangiocarcinoma cells was suppressed by treatment with small interfering RNA (siRNA) specific for c-Met, and resulted in decrease in phosphorylation of MEK1/2. Furthermore, treatment with siRNA specific for c-Met or MEK inhibitor U0126 inhibited cholangiocarcinoma cell invasion induced by HGF. Conclusions: These results indicated that HGF and c-Met involved in the mechanism of cholangiocarcinoma cell invasion. It implies a potential role for the inhibition of c-Met in the treatment of cholangiocarcinoma. © 2006 Elsevier Inc. All rights reserved.